| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Prostatic Neoplasms | 24 | 2023 | 1622 | 1.810 |
Why?
|
| Tissue Array Analysis | 6 | 2010 | 143 | 0.730 |
Why?
|
| Mouth Neoplasms | 1 | 2021 | 115 | 0.650 |
Why?
|
| Radiotherapy, Intensity-Modulated | 2 | 2017 | 102 | 0.640 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2021 | 873 | 0.590 |
Why?
|
| Oropharyngeal Neoplasms | 1 | 2021 | 283 | 0.550 |
Why?
|
| Prostatectomy | 7 | 2016 | 357 | 0.540 |
Why?
|
| Urinary Incontinence | 1 | 2016 | 77 | 0.500 |
Why?
|
| Nephrectomy | 1 | 2017 | 181 | 0.500 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 3 | 2007 | 1070 | 0.490 |
Why?
|
| Mesothelioma | 1 | 2017 | 94 | 0.490 |
Why?
|
| Pneumonectomy | 1 | 2017 | 148 | 0.490 |
Why?
|
| Radiotherapy | 1 | 2016 | 148 | 0.490 |
Why?
|
| Prosthesis Implantation | 1 | 2016 | 148 | 0.470 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2017 | 251 | 0.460 |
Why?
|
| Kidney Neoplasms | 1 | 2017 | 460 | 0.400 |
Why?
|
| Biomarkers, Tumor | 7 | 2010 | 1714 | 0.380 |
Why?
|
| Gene Expression Profiling | 4 | 2012 | 1911 | 0.370 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2023 | 1308 | 0.370 |
Why?
|
| Trans-Activators | 3 | 2008 | 827 | 0.330 |
Why?
|
| Prostate | 4 | 2023 | 448 | 0.300 |
Why?
|
| Oncogene Proteins, Fusion | 2 | 2007 | 233 | 0.300 |
Why?
|
| Ki-67 Antigen | 1 | 2008 | 118 | 0.300 |
Why?
|
| Chromosome Mapping | 2 | 2008 | 1124 | 0.260 |
Why?
|
| Lung Neoplasms | 1 | 2017 | 1791 | 0.250 |
Why?
|
| Radiosurgery | 2 | 2017 | 128 | 0.250 |
Why?
|
| Translocation, Genetic | 1 | 2007 | 362 | 0.250 |
Why?
|
| Tissue and Organ Harvesting | 1 | 2005 | 40 | 0.230 |
Why?
|
| Exons | 1 | 2007 | 833 | 0.230 |
Why?
|
| Aged | 18 | 2023 | 21664 | 0.220 |
Why?
|
| Adenocarcinoma | 2 | 2009 | 1069 | 0.220 |
Why?
|
| Prognosis | 9 | 2021 | 5058 | 0.220 |
Why?
|
| Male | 31 | 2023 | 65712 | 0.220 |
Why?
|
| Respiratory Tract Neoplasms | 1 | 2004 | 14 | 0.220 |
Why?
|
| Immunohistochemistry | 7 | 2010 | 1760 | 0.220 |
Why?
|
| Middle Aged | 19 | 2023 | 29299 | 0.210 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2004 | 72 | 0.210 |
Why?
|
| Transurethral Resection of Prostate | 1 | 2023 | 7 | 0.210 |
Why?
|
| Glutathione Transferase | 1 | 2004 | 163 | 0.210 |
Why?
|
| Lasers, Solid-State | 1 | 2023 | 19 | 0.200 |
Why?
|
| Lower Urinary Tract Symptoms | 1 | 2023 | 38 | 0.200 |
Why?
|
| Prostatic Hyperplasia | 1 | 2023 | 118 | 0.200 |
Why?
|
| Lymphoma, B-Cell, Marginal Zone | 2 | 2010 | 64 | 0.190 |
Why?
|
| Biopsy, Needle | 5 | 2010 | 236 | 0.190 |
Why?
|
| O(6)-Methylguanine-DNA Methyltransferase | 1 | 2021 | 21 | 0.180 |
Why?
|
| Humans | 38 | 2023 | 133454 | 0.180 |
Why?
|
| Genetic Predisposition to Disease | 5 | 2012 | 3474 | 0.180 |
Why?
|
| DNA Repair Enzymes | 1 | 2021 | 48 | 0.180 |
Why?
|
| DNA Modification Methylases | 1 | 2021 | 52 | 0.170 |
Why?
|
| Laser Therapy | 1 | 2023 | 252 | 0.170 |
Why?
|
| Transcriptional Regulator ERG | 3 | 2008 | 42 | 0.170 |
Why?
|
| Space Flight | 1 | 2021 | 117 | 0.160 |
Why?
|
| Prostate-Specific Antigen | 4 | 2023 | 272 | 0.150 |
Why?
|
| Head and Neck Neoplasms | 1 | 2004 | 693 | 0.140 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2021 | 510 | 0.140 |
Why?
|
| Spinal Neoplasms | 1 | 2017 | 63 | 0.130 |
Why?
|
| Urinary Sphincter, Artificial | 1 | 2016 | 5 | 0.130 |
Why?
|
| Aged, 80 and over | 7 | 2023 | 7183 | 0.120 |
Why?
|
| DNA-Binding Proteins | 3 | 2008 | 2159 | 0.120 |
Why?
|
| Adult | 12 | 2017 | 31880 | 0.110 |
Why?
|
| Burkitt Lymphoma | 2 | 2012 | 142 | 0.110 |
Why?
|
| Prostatic Secretory Proteins | 2 | 2010 | 3 | 0.110 |
Why?
|
| DNA Methylation | 1 | 2021 | 1146 | 0.110 |
Why?
|
| Aging | 1 | 2021 | 1303 | 0.110 |
Why?
|
| Glioblastoma | 1 | 2017 | 373 | 0.100 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2017 | 379 | 0.100 |
Why?
|
| Reoperation | 1 | 2016 | 866 | 0.100 |
Why?
|
| Guanylate Cyclase | 1 | 2012 | 39 | 0.100 |
Why?
|
| Lymphocytosis | 1 | 2012 | 14 | 0.100 |
Why?
|
| Prospective Studies | 3 | 2021 | 6649 | 0.100 |
Why?
|
| In Situ Hybridization, Fluorescence | 3 | 2009 | 790 | 0.100 |
Why?
|
| CARD Signaling Adaptor Proteins | 1 | 2012 | 44 | 0.100 |
Why?
|
| Neoplasm Staging | 3 | 2017 | 1388 | 0.090 |
Why?
|
| Germ-Line Mutation | 2 | 2012 | 368 | 0.090 |
Why?
|
| Gene Expression Regulation, Neoplastic | 3 | 2010 | 2114 | 0.090 |
Why?
|
| Risk Factors | 5 | 2017 | 11054 | 0.090 |
Why?
|
| RNA, Messenger | 2 | 2007 | 2899 | 0.090 |
Why?
|
| Genes, BRCA2 | 1 | 2010 | 49 | 0.090 |
Why?
|
| BRCA2 Protein | 1 | 2010 | 52 | 0.080 |
Why?
|
| Oncogenes | 1 | 2010 | 179 | 0.080 |
Why?
|
| Genotype | 5 | 2010 | 2804 | 0.080 |
Why?
|
| BRCA1 Protein | 1 | 2010 | 82 | 0.080 |
Why?
|
| Myeloid Differentiation Factor 88 | 1 | 2010 | 101 | 0.080 |
Why?
|
| Lung | 1 | 2017 | 1554 | 0.080 |
Why?
|
| Molecular Targeted Therapy | 1 | 2012 | 406 | 0.080 |
Why?
|
| B-Lymphocytes | 1 | 2012 | 549 | 0.080 |
Why?
|
| Chromosomes, Human, Pair 8 | 1 | 2009 | 82 | 0.080 |
Why?
|
| Trypsin Inhibitor, Kazal Pancreatic | 1 | 2008 | 6 | 0.080 |
Why?
|
| Proto-Oncogene Proteins c-cbl | 1 | 2008 | 10 | 0.080 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2010 | 147 | 0.080 |
Why?
|
| Treatment Outcome | 4 | 2023 | 12987 | 0.080 |
Why?
|
| Racemases and Epimerases | 1 | 2008 | 11 | 0.080 |
Why?
|
| Breast Neoplasms | 3 | 2010 | 2759 | 0.080 |
Why?
|
| Radiotherapy, Conformal | 1 | 2008 | 63 | 0.070 |
Why?
|
| Prostatic Intraepithelial Neoplasia | 1 | 2007 | 43 | 0.070 |
Why?
|
| Proto-Oncogene Proteins c-ets | 1 | 2007 | 59 | 0.070 |
Why?
|
| Genes, Neoplasm | 1 | 2007 | 90 | 0.070 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 1 | 2008 | 152 | 0.070 |
Why?
|
| Neovascularization, Pathologic | 1 | 2008 | 261 | 0.060 |
Why?
|
| Transcription Factors | 2 | 2008 | 2702 | 0.060 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2017 | 3818 | 0.060 |
Why?
|
| Quantitative Trait Loci | 1 | 2008 | 319 | 0.060 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2010 | 790 | 0.060 |
Why?
|
| Genetic Markers | 1 | 2007 | 631 | 0.060 |
Why?
|
| Ovarian Neoplasms | 1 | 2010 | 464 | 0.060 |
Why?
|
| Li-Fraumeni Syndrome | 1 | 2006 | 52 | 0.060 |
Why?
|
| Alleles | 1 | 2010 | 1704 | 0.060 |
Why?
|
| Tissue Culture Techniques | 1 | 2005 | 68 | 0.060 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2007 | 1326 | 0.060 |
Why?
|
| Chromosome Aberrations | 1 | 2007 | 626 | 0.060 |
Why?
|
| Precancerous Conditions | 1 | 2007 | 288 | 0.060 |
Why?
|
| Disease-Free Survival | 2 | 2010 | 969 | 0.060 |
Why?
|
| Receptors, Immunologic | 1 | 2005 | 121 | 0.060 |
Why?
|
| Case-Control Studies | 3 | 2010 | 3632 | 0.060 |
Why?
|
| Female | 5 | 2021 | 71471 | 0.050 |
Why?
|
| Tobacco, Smokeless | 1 | 2004 | 14 | 0.050 |
Why?
|
| Genomics | 1 | 2012 | 1671 | 0.050 |
Why?
|
| Mutation | 4 | 2010 | 6274 | 0.050 |
Why?
|
| Retrospective Studies | 4 | 2017 | 17413 | 0.050 |
Why?
|
| Membrane Proteins | 2 | 2008 | 1605 | 0.050 |
Why?
|
| Holmium | 1 | 2023 | 10 | 0.050 |
Why?
|
| India | 1 | 2004 | 238 | 0.050 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 2 | 2017 | 81 | 0.050 |
Why?
|
| Carrier Proteins | 1 | 2008 | 1063 | 0.050 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2009 | 2935 | 0.050 |
Why?
|
| Radiography | 1 | 2005 | 825 | 0.050 |
Why?
|
| Preoperative Care | 1 | 2005 | 371 | 0.050 |
Why?
|
| Young Adult | 1 | 2017 | 9880 | 0.050 |
Why?
|
| Androgen Antagonists | 1 | 2023 | 131 | 0.050 |
Why?
|
| High-Throughput Nucleotide Sequencing | 3 | 2012 | 959 | 0.050 |
Why?
|
| Nuclear Proteins | 1 | 2008 | 1334 | 0.050 |
Why?
|
| Disease Progression | 1 | 2008 | 2235 | 0.050 |
Why?
|
| Cohort Studies | 2 | 2008 | 5176 | 0.050 |
Why?
|
| Regression Analysis | 1 | 2004 | 831 | 0.050 |
Why?
|
| Homeodomain Proteins | 1 | 2005 | 585 | 0.050 |
Why?
|
| RNA | 1 | 2005 | 601 | 0.050 |
Why?
|
| Child, Preschool | 1 | 2017 | 14758 | 0.040 |
Why?
|
| Laboratories | 1 | 2021 | 89 | 0.040 |
Why?
|
| Radiotherapy Dosage | 1 | 2001 | 224 | 0.040 |
Why?
|
| Polymerase Chain Reaction | 3 | 2010 | 1632 | 0.040 |
Why?
|
| Immunophenotyping | 1 | 2001 | 342 | 0.040 |
Why?
|
| Formaldehyde | 2 | 2010 | 40 | 0.040 |
Why?
|
| Telomere | 1 | 2021 | 230 | 0.040 |
Why?
|
| RNA Interference | 2 | 2012 | 540 | 0.040 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2012 | 866 | 0.040 |
Why?
|
| Genetic Variation | 1 | 2006 | 1611 | 0.040 |
Why?
|
| NF-kappa B | 2 | 2012 | 482 | 0.040 |
Why?
|
| Biomedical Research | 1 | 2005 | 556 | 0.040 |
Why?
|
| Adolescent | 1 | 2017 | 20497 | 0.040 |
Why?
|
| Smoking | 1 | 2004 | 1139 | 0.040 |
Why?
|
| Cancer Pain | 1 | 2017 | 28 | 0.030 |
Why?
|
| Narcotics | 1 | 2017 | 64 | 0.030 |
Why?
|
| Craniotomy | 1 | 2017 | 109 | 0.030 |
Why?
|
| Child | 1 | 2017 | 25700 | 0.030 |
Why?
|
| Molecular Sequence Data | 2 | 2012 | 3970 | 0.030 |
Why?
|
| Spine | 1 | 2017 | 145 | 0.030 |
Why?
|
| Survival Analysis | 2 | 2010 | 1596 | 0.030 |
Why?
|
| Follow-Up Studies | 2 | 2017 | 5487 | 0.030 |
Why?
|
| Biopsy | 1 | 2017 | 1301 | 0.030 |
Why?
|
| Palliative Care | 1 | 2017 | 457 | 0.030 |
Why?
|
| Signal Transduction | 3 | 2012 | 4882 | 0.030 |
Why?
|
| Cyclin D3 | 1 | 2012 | 11 | 0.030 |
Why?
|
| Inhibitor of Differentiation Proteins | 1 | 2012 | 12 | 0.020 |
Why?
|
| Splenomegaly | 1 | 2012 | 33 | 0.020 |
Why?
|
| Receptors, Antigen, B-Cell | 1 | 2012 | 33 | 0.020 |
Why?
|
| Genes, myc | 1 | 2012 | 107 | 0.020 |
Why?
|
| Cyclin-Dependent Kinase 6 | 1 | 2012 | 50 | 0.020 |
Why?
|
| Immunoblotting | 1 | 2012 | 317 | 0.020 |
Why?
|
| Cluster Analysis | 1 | 2012 | 438 | 0.020 |
Why?
|
| Microscopy, Confocal | 1 | 2012 | 370 | 0.020 |
Why?
|
| Interleukin-1 Receptor-Associated Kinases | 1 | 2010 | 22 | 0.020 |
Why?
|
| Receptors, Interleukin-1 | 1 | 2010 | 29 | 0.020 |
Why?
|
| Polymorphism, Single-Stranded Conformational | 1 | 2010 | 73 | 0.020 |
Why?
|
| Janus Kinases | 1 | 2010 | 33 | 0.020 |
Why?
|
| Hydrophobic and Hydrophilic Interactions | 1 | 2010 | 65 | 0.020 |
Why?
|
| Tissue Fixation | 1 | 2010 | 41 | 0.020 |
Why?
|
| Toll-Like Receptors | 1 | 2010 | 85 | 0.020 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2012 | 351 | 0.020 |
Why?
|
| Mutant Proteins | 1 | 2010 | 118 | 0.020 |
Why?
|
| Cell Line, Tumor | 2 | 2010 | 3725 | 0.020 |
Why?
|
| Preventive Medicine | 1 | 2010 | 21 | 0.020 |
Why?
|
| Loss of Heterozygosity | 1 | 2010 | 135 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2012 | 836 | 0.020 |
Why?
|
| Cell Cycle | 1 | 2012 | 626 | 0.020 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2012 | 406 | 0.020 |
Why?
|
| Fixatives | 1 | 2009 | 14 | 0.020 |
Why?
|
| Paraffin Embedding | 1 | 2009 | 41 | 0.020 |
Why?
|
| Amino Acid Substitution | 1 | 2010 | 412 | 0.020 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2010 | 168 | 0.020 |
Why?
|
| Risk Reduction Behavior | 1 | 2010 | 148 | 0.020 |
Why?
|
| Microdissection | 1 | 2008 | 14 | 0.020 |
Why?
|
| Gadolinium DTPA | 1 | 2009 | 50 | 0.020 |
Why?
|
| Kallikreins | 1 | 2008 | 31 | 0.020 |
Why?
|
| Pedigree | 1 | 2012 | 1693 | 0.020 |
Why?
|
| Protein Structure, Tertiary | 1 | 2010 | 783 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2017 | 2190 | 0.020 |
Why?
|
| STAT3 Transcription Factor | 1 | 2010 | 230 | 0.020 |
Why?
|
| Hypoxia-Inducible Factor 1 | 1 | 2008 | 19 | 0.020 |
Why?
|
| Echo-Planar Imaging | 1 | 2008 | 23 | 0.020 |
Why?
|
| Data Collection | 1 | 2010 | 397 | 0.020 |
Why?
|
| Cell Survival | 1 | 2010 | 888 | 0.020 |
Why?
|
| Base Sequence | 1 | 2012 | 3169 | 0.020 |
Why?
|
| Cell Hypoxia | 1 | 2008 | 104 | 0.020 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2008 | 433 | 0.020 |
Why?
|
| Osteopontin | 1 | 2008 | 51 | 0.020 |
Why?
|
| Neoplasm Proteins | 1 | 2012 | 716 | 0.020 |
Why?
|
| Mutation, Missense | 1 | 2012 | 927 | 0.020 |
Why?
|
| Disease Susceptibility | 1 | 2009 | 319 | 0.020 |
Why?
|
| Sequence Analysis, RNA | 1 | 2010 | 429 | 0.020 |
Why?
|
| Australia | 1 | 2008 | 190 | 0.020 |
Why?
|
| United Kingdom | 1 | 2008 | 237 | 0.020 |
Why?
|
| Probability | 1 | 2008 | 335 | 0.020 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2009 | 234 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2010 | 1699 | 0.020 |
Why?
|
| Serine Endopeptidases | 1 | 2007 | 204 | 0.020 |
Why?
|
| Reference Values | 1 | 2008 | 744 | 0.020 |
Why?
|
| Transfection | 1 | 2008 | 1086 | 0.020 |
Why?
|
| RNA, Small Interfering | 1 | 2008 | 711 | 0.020 |
Why?
|
| Amino Acid Sequence | 1 | 2010 | 2785 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2008 | 1136 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2008 | 1135 | 0.020 |
Why?
|
| Receptors, Scavenger | 1 | 2005 | 3 | 0.010 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2008 | 448 | 0.010 |
Why?
|
| Scavenger Receptors, Class A | 1 | 2005 | 9 | 0.010 |
Why?
|
| Contrast Media | 1 | 2009 | 513 | 0.010 |
Why?
|
| Genes, p53 | 1 | 2006 | 234 | 0.010 |
Why?
|
| E2F3 Transcription Factor | 1 | 2004 | 11 | 0.010 |
Why?
|
| Cytokines | 1 | 2010 | 1395 | 0.010 |
Why?
|
| DNA, Complementary | 1 | 2005 | 471 | 0.010 |
Why?
|
| Proportional Hazards Models | 1 | 2008 | 1478 | 0.010 |
Why?
|
| Epithelial Cells | 1 | 2008 | 940 | 0.010 |
Why?
|
| Gene Expression | 1 | 2008 | 1614 | 0.010 |
Why?
|
| Gene Amplification | 1 | 2004 | 247 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2009 | 2156 | 0.010 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2008 | 1198 | 0.010 |
Why?
|
| DNA Damage | 1 | 2006 | 542 | 0.010 |
Why?
|
| Genome, Human | 1 | 2009 | 1348 | 0.010 |
Why?
|
| Genetic Testing | 1 | 2008 | 1084 | 0.010 |
Why?
|
| Genome-Wide Association Study | 1 | 2009 | 1871 | 0.010 |
Why?
|
| Algorithms | 1 | 2008 | 1724 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2008 | 3682 | 0.010 |
Why?
|
| Phenotype | 1 | 2006 | 4525 | 0.010 |
Why?
|